Therapeutic Response

CD33 + status confers therapeutic sensitivity to Cytarabine in combination with Daunorubicin and Gemtuzumab ozogamicin in patients with Acute Lymphoid Leukemia.

Statements

Source and description

Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction). NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for reimbursement as a treatment option for the treatment of patients aged 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukemia.